Advertisement

Bausch + Lomb lands a panel date with the FDA to review its Trulign Toric vision-correcting implant.

Bausch + Lomb logo

Eye care giant Bausch + Lomb won a date with the FDA for review of its Trulign Toric intraocular lens for improving vision in patient who have undergone cataract surgery.

On April 8, 2013, the FDA's Ophthalmic Devices Panel will review clinical data and cast a vote on the Trulign Toric implant in treatment of patients with vision impairment as a result of aphakia and postoperative refractive astigmatism.

Advertisement
Advertisement